ArticlePractical laboratory medicine2025
Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients.
Article in Practical laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Charting the blueprint: a bibliometric analysis reveals future strategies in lung cancer targeted therapy (2003-2025).Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study examines the genetic and clinical profiles of Vietnamese patients with non-small cell lung cancer (NSCLC), focusing on mutations in seven driver genes: Materials and methods: A cross-sectional study of 299 NSCLC patients at the University Medical Center, Ho Chi Minh City (2019-2022) recorded demographics, smoking history, and tumor stage. Pre-treatment samples were analyzed via massively parallel sequencing, and survival analysis assessed the impact of Results: Most patients (88.6 %) were diagnosed at stage IV. Conclusions: Genetic profiling in Vietnamese NSCLC patients reveals a high prevalence of actionable driver mutations, supporting the integration of routine molecular testing into NSCLC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.